Falling sales, rising competition behind Lilly/Chugai move to end Japan Evista pact?
This article was originally published in Scrip
Lilly and Roche's Japanese affiliate Chugai have decided to discontinue their agreement for the co-marketing in Japan of Lilly's osteoporosis drug Evista (raloxifene), the move apparently being prompted by changing commercial priorities at both firms.
You may also be interested in...
Join us for a brief audio tour around the past week's key developments in the global biopharma industry, in this podcast version of Scrip's Five Must-Know Things.
Given its ever-growing role as a critical component of the global biopharma industry, you can’t afford not to be up to speed on Asia. This biweekly selection of insights from our experienced on-the-ground team will help.
Plus deals involving Takeda/OrigiMed, Amcure/Hinova, AUM/Newsoara, Taiho/Lung Therapeutics, 3D Medicines/Aravive, HitGen/Baiyunshan, Dong-A/Jiangsu Hengrui, and Crescita/Juyou.